The Big Impact of Skinny Labels: What the Supreme Court’s Decision in Hikma v. Amarin May Mean for Patent Strategy
External Article
Baker Botts Partner Rob Maier explains how the Supreme Court’s review of Hikma v. Amarin could reshape when generic drugmakers face induced‑infringement liability for marketing products sold under FDA‑approved skinny labels.
For a complete copy of this article from New York Law Journal, please click the title link below:
